This recombinant monoclonal antibody is developed as a research-grade biosimilar to Zalifrelimab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, thereby dampening immune responses and maintaining peripheral tolerance. Dysregulation of CTLA4-mediated immune suppression plays a significant role in cancer immune evasion, autoimmune diseases, and transplant rejection, making it a valuable target for immunotherapy research.
Zalifrelimab represents an investigational anti-CTLA4 antibody designed to enhance anti-tumor immunity by blocking CTLA4's inhibitory signals, thereby promoting T-cell activation and proliferation. This biosimilar antibody provides researchers with a reliable tool for studying CTLA4 biology, investigating immune checkpoint mechanisms, evaluating combination immunotherapy strategies, and exploring T-cell-mediated immune responses in various disease models. It serves as an essential reagent for immunology and oncology research programs focused on understanding and modulating adaptive immunity.
Email: support@cusabio.com
Distributors Worldwide